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INTRODUCTION
Median survival time, even with the best suppor-
tive care, for patients with unresectable or metastatic
gastric cancer is only 3.1 months (1). Although
peritoneum is the most common metastatic site of
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advanced gastric cancer, a standard regimen has
not been established despite the number of trials
and the survival rate is very low.
Recently new chemotherapy agents have been de-
veloped. In particular S-1 revealed a high response
rate of 49% for advanced gastric cancer in late phase
II study (2), which has been widely accepted as a
key drug even for adjuvant setting in Japan (3).
Taxanes stabilize and excessively form microtu-
bules, which is a different mechanism from other
agents. In phase II study, response rate of paclitaxel
(PTX) for advanced gastric cancer was 21% and not
affected by differentiation of adenocarcinoma (4, 5).
High concentrations approximately 1000 times of
PTX in the peritoneal cavity maintained compared
with those in serum after intraperitoneal administra-
tion because of fat solubility and heavy molecular
weight ; 853.92 (6). Excellent pharmacokinetics and
anti-tumor effect to the peritoneal dissemination
of gastric cancer was reported in the experimental
model (7).
It is considered that S-1 and PTX is one of the
best combinations for the treatment peritoneal me-
tastasis of gastric cancer. The aim of this study is to
determine the appropriate doses and feasibility of




Patients with peritoneal metastasis of advanced
gastric cancer were eligible for this clinical trial. Be-
fore initiation of the study, relevant study documen-
tation was submitted to and approved by the respon-
sible ethics committee : the University of Tokushima
hospital clinical research Ethical Review Board,
Tokushima, Japan.
The guidelines of the World Medical Associa-
tion Declaration of Helsinki in its revised edition
(Edinburgh, Scotland, October 2000) and other ap-
plicable regulatory requirements were strictly fol-
lowed. Written informed consent was obtained from
each patient before any study-specific screening pro-
cedures were undertaken.
Inclusion criteria
Patients aged 20-75 years, had to have histologi-
cally or cytologically confirmed peritoneal metastasis
of gastric cancer using laparoscopy under general
anesthesia, who had not received abdominal surgery
and any prior chemotherapy regimens.
Exclusion criteria
Patients with ischemic heart disease that needed
medication, liver cirrhosis, lung fibrosis, pneumonia,
intestinal bleeding or other severe complications
were excluded.
Treatment plan
An initial laparoscopy was performed under gen-
eral anesthesia for the patients with advanced gas-
tric cancer histologically diagnosed. Peritoneal me-
tastasis was histologically confirmed by removal of
disseminated nodules or peritoneal cytology.
The catheter for intraperitoneal infusion of PTX
was passed through the wound of trocar port in the
right side of the umbilicus, which was connected to
the port implanted in the abdominal wall for the
patient diagnosed peritoneal metastasis.
S-1 was orally administered with a fixed quantity
(Dose 80 mg : Body Surface Area (BSA)1.25 m2,
100 mg : 1.25 BSA  1.5 m2, 120 mg : BSA  1.5
m2) for 14 days. PTX was infused intraperitoneally
through the implanted catheter at day1 and 14.
Dose of PTX was escalated ; level I : 40 mg/m2, level
II : 60 mg/m2, level III : 80 mg/m2 level IV : 90 mg/
m2, level V : 100 mg/m2. Intraperitoneal PTX with
S-1 was repeated two cycles every four weeks.
Adverse events were coded according to the Na-
tional Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE), version 3.0.
Dose Limiting Toxicity (DLT) was defined two pa-
tients had nonhematologic or hematologic grade 3
or greater adverse events. If one patient had Grade 3
or more adverse events, the cohort was expanded to
three patients owing to occurrence of a DLT. As a
result, the dose of PTX was increased to the level
that two patients had a DLT in turn. The Maximum
Tolerated Dose (MTD) was defined as one escala-
tion level lower than that DLT was confirmed. Rec-
ommended dose (RD) was defined as one level
lower than MTD.
Analytic methods and pharmocokinetics
Blood samples for pharmacokinetic analysis were
drawn before infusion, at 4, 8, 12, 24 and 48 h after
the infusion of PTX. Ascites samples were aspirated
through the catheter for PTX infusion at the same
time points. High performance liquid chromatogra-
phy (Ultra-Violet absorbance detector : Ultra-violet
of 227 nm in wave length) was used to analyze PTX
concentrations of serum and ascites in SRL, Inc




Patient demographics are shown in Table 1. The
18 patients were enrolled in this study after histologi-
cally confirming peritoneal metastasis. Two of the
18 patients had adenocarcninoma cells in peritoneal
cytology without macroscopically detected metas-
tatic nodules. Curative operation was not impossi-
ble for all 18 patients.
Clinical safety and tolerability
All 18 enrolled patients were evaluated for safety.
A summary of the patient- and investigator-reported
drug related clinical adverse events is shown in
Table 2. Current regimen was generally well toler-
ated, with 6 patients clinically significant drug-related
adverse events. The most frequently reported ad-
verse event was Grade 3 leukocytopenia. Grade 1
or 2 anemia, vomiting and abdominal pain were
confirmed.
The 40, 80, 90 and 100 mg/m2 cohort enrolled
three patients. After the one patient had Grade 3
leukocytopenia in 60 mg/m2 cohort, this cohort was
expanded to 6 patients without Grade 3 or more ad-
verse events. Grade 3 leukocytopenia was confirmed
consecutively 2 patients in 100 mg/m2 cohort.
DLT was leukocytopenia, MTD was 90 mg/m2
and RD was 80 mg/m2, respectively.
Pharmocokinetics of PTX
The average serum PTX concentrations in 40, 60,
80 and 90 mg/m2 cohort were maintained between
the lower limit of cytotoxic effects and upper limit
of blood system disorder, which were over upper
limit of blood system disorder in all 3 patients of
100 mg/m2 cohort. In all cohorts, PTX concentra-
tions in the ascites were approximately 1000 folds
higher than those in serum for 48 hours after the
infusion (Figure 1).
Clinical activity
All 18 patients were evaluated for efficacy. Ob-
jective clinical response was assessed according to
Response Evaluation Criteria in Solid Tumors (RE-
CIST). The 2 patients had partial response. The 15
patients was recorded as stable disease, however,
positive adenocarcinoma cells in peritoneal cytology
became negative in 2 patients, remarkable decrease
of ascites was found in 2 patients. Down staging
according to the 13th Japanese Classification of Gas-
tric Carcinoma was possible in 2 patients (2 : posi-
tive cytology became negative). There was one pa-
tient classified as having progressive disease.
Gastrectomy was performed for 12 of 18 patients,
which had curative potential in the patients with
down staging. The median survival time was 11
months. Survival time of the 2 patients whose posi-
tive cytology became negative was 32 and 48months,
respectively (Table 3).
Table 1 : Patient demographics
Sex (male/female) 14/4
Age (years) (median/min/max) 56/49/75
WHO Performance status (0/1) 14/4
Macroscopic types III / IV 10/8
Histological typing well/poorly differentiated 3/15
Positive adenocarcinoma cells in peritoneal cytology 18
Macroscopically detected metastatic nodules 16
Gastrectomy 12
Table 2 : Drug-related adverse events







Abdominal pain 1 (5.6%)
Figure 1 : Pharmacokinetics of PTX
The PTX concentrations in 40, 60, 80 and 90 mg/m2 cohort re-
mained in the optimal range. In 100 mg/m2 cohort, the PTX con-
centrations were over upper limit of blood system. PTX concen-
trations in the ascites were approximately 1000 times higher
than those in serum.
N. Kurita, et al. Intraperitoneal infusion of paclitaxel with S-1136
DISCUSSION
Intraperitoneal infusion of PTX was generally well
tolerated. The most frequently reported adverse
event was Grade 3 leukocytopenia. DLT was leu-
kocytopenia, MTD was 90 mg/m2 and RD was 80
mg/m2, respectively. These findings were supported
by pharmacokinetics of PTX.
Because S-1 is the most widely accepted drug for
gastric cancer in Japan, a lot of combination trials
based on S-1 have been performed (8-10). Median
overall survival was significantly longer in patients
assigned to S-1 plus cisplatin (13.0 months) than
in those assigned to S-1 alone (11.0 months) in the
Phase III trial for advanced gastric cancer, however,
peritoneal dissemination held 34%, 24% of each
group, respectively (8). Significant differences in
overall survival compared with S-1 alone revealed
in any other regimens. It has not been established
standard regimens for peritoneal metastasis of gas-
tric cancer.
Intraperitoneal PTX in the phase II trial for the
patients with small-volume residual carcinomas of
the ovary, fallopian tube, or peritoneum was well
tolerated, which included only moderate abdominal
pain (grade 2 : 15.7%, grade 3 ; 1.3%) and minimal
neutropenia (grade 2 ; 3.9% ; grade 3 ; 1.3%) (11).
The incidence of Grade 3 neutropenia were ob-
served in 32% of the patients with advanced gastric
cancer in the treatment schedule comprised an in-
travenous infusion of 80 mg/m2 PTX , repeated
weekly three times for 4 weeks (12). These data
suggested that intraperitoneal administration of PTX
did not increase the incidence of drug-induced tox-
icities (13).
A pharmacokinetics study demonstrated that the
PTX concentration in ascites remained in the range
of the lower limit of cytotoxic effects and upper limit
of blood system disorder from 4 to 72 hours after in-
travenous infusion of 60 and 80 mg/m2 PTX. On the
other hand, plasma concentrations of PTX were over
upper limit of blood system disorder at 4 hours (14).
In contrast, the PTX concentrations in 40, 60, 80
and 90 mg/m2 cohort in this study remained in the
optimal range. In 100 mg/m2 cohort, the PTX con-
centrations were over upper limit of blood system.
PTX concentrations in the ascites were approxi-
mately 1,000 folds higher than those in serum.
A major advantage after intraperitoneal delivery
of PTX is high concentration in the peritoneal cavity
(550-2,000 folds) compared with the systemic com-
partment (13). Drug exposure of high concentration
is considered to have an advantage because anti-
tumor effects increased dose dependent manner
Table 3 : Clinical activity
Case Level RECIST Down staging Gastrectomy Prognosis Survival time(months)
1 1 PR - + death 8
2 1 SD - + death 10
3 1 SD +* + alive 48
4 2 SD - + death 17
5 2 PR - + death 21
6 2 SD - - death 15
7 2 SD - - death 14
8 2 SD - + death 10
9 2 SD - - death 11
10 3 SD +* + alive 32
11 3 SD - + alive 30
12 3 SD - + death 8
13 4 SD - + death 9
14 4 SD - - death 6
15 4 SD - + death 5
16 5 PD - - death 14
17 5 SD - - death 7
18 5 SD - + alive 11
* Positive adenocarcinoma cells in peritoneal cytology became negative.
The Journal of Medical Investigation Vol. 58 February 2011 137
as far as could be seen there were no severe tox-
icities in the experimental model (7).
Although this study is a phase I study, the re-
sponse rate and survival could not be described
exactly, two patients with positive adnocarcinoma
cells and no macroscopically detected disseminate
nodules had a long survival of over 30 months. The
overall 5-year survival (43.8%) of advanced gastric
cancer patients with intraperitoneal free cancer cells
without overt peritoneal metastasis (CY+/P-) after
extensive intraoperative peritoneal lavage followed
by the intraperitoneal chemotherapy (EIPL-IPC:
peritoneal lavage of 10 times using 1 L of physiologi-
cal saline following cisplatin at a dose of 100 mg/
body into the peritoneal cavity) was significantly
better than that of the intraperitoneal chemotherapy
(4.6%) and the surgery alone (0%) (15). It is impor-
tant to detect positive adenocarcinoma cells in the
peritoneal cavity to improve survival of the patients
with peritoneal metastasis (16).
Concerning patients with macroscopically de-
tected peritoneal metastasis, the utility of peritonec-
tomy with chemohyperthermic peritoneal perfusion
(CHPP) was reported, however, there are some
problems regarding peritonectomy : complicated pro-
cedures and CHPP : severe stress to the patients and
needs of specific and expensive instruments (17).
Fat solubility of PTX is suitable for intraperito-
neal infusion, in contrast, Cremophor EL and etha-
nol is necessary as a solvent for clinical use, which
causes acute hypersensitivity (18). For better and
safe drug delivery system, various modifications of
PTX have been developed and phase I trials were
reported (19-21). Intraperitoneal PTX using the
water-soluble solvent revealed excellent pharma-
cokinetics compared with Cremophor EL (22).
Intraperitoneal PTX including new modified drugs
has high potentials to improve survival for the peri-
toneal metastasis of gastric cancer.
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